Pulse Biosciences Reports Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Pulse Biosciences, Inc. (PLSE) Misses Q3 EPS by 7c
November 9, 2020 5:05 PM ESTPulse Biosciences, Inc. (NASDAQ: PLSE) reported Q3 EPS of ($0.51), $0.07 worse than the analyst estimate of ($0.44).
Recent Highlights
Submitted a 510(k) Premarket Notification application to the U.S. Food and Drug Administration (FDA) for the CellFX® System seeking to obtain initial clearance for a general dermatologic indication. Potential clearance remains on track to be received as early as the first quarter of 2021.Received FDA Investigational Device Exemption (IDE) approval and completed enrollment ahead... More